Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers

Otolaryngologic Clinics of North America

Volumn 45, Issue 4, 2012, Pages 807-822

  Best, Simon R ^a   Niparko, Kevin J ^b   Pai, Sara I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

HPV head and neck cancer; Immunotherapy; Oropharyngeal cancer; Vaccines

Indexed keywords

BEVACIZUMAB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IPILIMUMAB; NIVOLUMAB; PLACEBO; PROTEIN E6; PROTEIN E7; VASCULOTROPIN; VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CLINICAL PRACTICE; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPLASIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OROPHARYNX CANCER; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RISK; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT RESPIRATORY PAPILLOMATOSIS; REVIEW; RISK REDUCTION; TONSIL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS REPLICATION;

FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, DNA;

EID: 84863869305     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2012.04.005     Document Type: Review

References (77)

1. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
2. Giuliano A.R., Lee J.H., Fulp W., et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011, 377(9769):932-940.
3. Castle P.E., Schiffman M., Herrero R., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191(11):1808-1816.
4. Munoz N., Mendez F., Posso H., et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004, 190(12):2077-2087.
5. Gillison M.L., Broutian T., Pickard R.K., et al. Prevalence of oral HPV Infection in the United States, 2009-2010. JAMA 2012, 307(7):693-703.
6. D'Souza G., Agrawal Y., Halpern J., et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009, 199(9):1263-1269.
7. D'Souza G., Fakhry C., Sugar E.A., et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007, 121(1):143-150.
8. Buck C.B., Cheng N., Thompson C.D., et al. Arrangement of L2 within the papillomavirus capsid. J Virol 2008, 82(11):5190-5197.
9. Buck C.B., Thompson C.D., Pang Y.Y., et al. Maturation of papillomavirus capsids. J Virol 2005, 79(5):2839-2846.
10. Kines R.C., Thompson C.D., Lowy D.R., et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 2009, 106(48):20458-20463.
11. Peitsaro P., Johansson B., Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002, 40(3):886-891.
12. Lazo P.A. The molecular genetics of cervical carcinoma. Br J Cancer 1999, 80(12):2008-2018.
13. Pett M., Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol 2007, 212(4):356-367.
14. Ragin C.C., Modugno F., Gollin S.M. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007, 86(2):104-114.
15. Howley P.M. Role of the human papillomaviruses in human cancer. Cancer Res 1991, 51(Suppl 18):5019s-5022s.
16. Bourgault Villada I., Moyal Barracco M., Ziol M., et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res 2004, 64(23):8761-8766.
17. Paternoster D.M., Cester M., Resente C., et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008, 40(6):1877-1880.
18. Fruchter R.G., Maiman M., Sedlis A., et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996, 87(3):338-344.
19. Moscicki A.B., Ellenberg J.H., Farhat S., et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004, 190(1):37-45.
20. Best S.R., Peng S., Juang C.M., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8 + T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27(40):5450-5459.
21. Cheng W.F., Hung C.F., Chai C.Y., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108(5):669-678.
22. Frazer I.H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009, 384(2):410-414.
23. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(6):1911-1919.
24. Carter J.J., Madeleine M.M., Shera K., et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001, 61(5):1934-1940.
25. Jochmus-Kudielka I., Schneider A., Braun R., et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989, 81(22):1698-1704.
26. Anderson K.S., Wong J., D'Souza G., et al. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer 2011, 104(12):1896-1905.
27. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994, 68(12):8056-8063.
28. Welters M.J., de Jong A., van den Eeden S.J., et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003, 63(3):636-641.
29. de Jong A., van Poelgeest M.I., van der Hulst J.M., et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004, 64(15):5449-5455.
30. Nakagawa M., Stites D.P., Farhat S., et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997, 175(4):927-931.
31. Hemminki K., Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006, 15(7):1413-1414.
32. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002, 2(1):59-65.
33. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 24(Suppl 1):S16-S22.
34. Woodworth C.D. HPV innate immunity. Front Biosci 2002, 7:d2058-d2071.
35. Ashrafi G.H., Haghshenas M.R., Marchetti B., et al. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005, 113(2):276-283.
36. Hasan U.A., Bates E., Takeshita F., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007, 178(5):3186-3197.
37. Huang S.M., McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 2002, 76(17):8710-8721.
38. Lee S.J., Cho Y.S., Cho M.C., et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001, 167(1):497-504.
39. Barnard P., McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259(2):305-313.
40. Li S., Labrecque S., Gauzzi M.C., et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18(42):5727-5737.
41. Nees M., Geoghegan J.M., Hyman T., et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001, 75(9):4283-4296.
42. Zhou J., Sun X.Y., Stenzel D.J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185(1):251-257.
43. Lowy D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116(5):1167-1173.
44. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
45. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927. FUTURE II Study Group.
46. GlaxoSmithKline. Clinical trial NCT00423046. cited 2012. Available at: Accessed May 24, 2012. http://clinicaltrials.gov/ct2/show/NCT00423046.
47. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364(5):401-411.
48. CDC National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep 2011, 117(60):1117-1123.
49. Bogaards J.A., Coupe V.M., Xiridou M., et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22(4):505-515.
50. CDC. Genital HPV infection - fact sheet 2011. Available at: Accessed May 24, 2012. http://www.cdc.gov/std/hpv/stdfact-hpv.htm.
51. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29(32):4294-4301.
52. Kenter G.G., Welters M.J., Valentijn A.R., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361(19):1838-1847.
53. Trimble C.L., Peng S., Kos F., et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009, 15(1):361-367.
54. Sidney Kimmel Comprehensive Cancer Center. Clinical trial NCT01493154 - Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients. Available at: Accessed May 24, 2012. http://clinicaltrials.gov/ct2/show/NCT01493154.
55. Cheng W.F., Hung C.F., Chen C.A., et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 2005, 23(29):3864-3874.
56. Tseng C.W., Hung C.F., Alvarez R.D., et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008, 14(10):3185-3192.
57. Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev 2005, 24(1):129-146.
58. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
59. Pim D., Collins M., Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992, 7(1):27-32.
60. Crusius K., Auvinen E., Steuer B., et al. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 1998, 241(1):76-83.
61. Lyford-Pike S., Westra W.H., Loyo M., et al. Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis. Histopathology 2010, 57(5):768-770.
62. Johnston D., Hall H., DiLorenzo T.P., et al. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res 1999, 59(4):968-974.
63. NCI. Clinical Trial NCT01084083 - Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery. Available at: Accessed May 24, 2012. http://clinicaltrials.gov/ct2/show/NCT01084083.
64. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
65. Hong A., Dobbins T., Lee C.S., et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer 2010, 46(11):2088-2096.
66. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000, 19(40):4611-4620.
67. Walker J., Smiley L.C., Ingram D., et al. Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration. Virology 2011, 410(2):283-290.
68. Kim S.H., Juhnn Y.S., Kang S., et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci 2006, 63(7-8):930-938.
69. NCI. Clinical trial NCT00081263 - Celecoxib in treating patients with cervical intraepithelial neoplasia. Available at: Accessed May 24, 2012. http://clinicaltrials.gov/ct2/show/NCT00081263.
70. North Shore Long Island Jewish Health System. Clinical trial NCT00571701 - Study of Celebrex (celecoxib) in patients with recurrent respiratory papillomatosis. Available at: Accessed May 24, 2012. http://clinicaltrials.gov/ct2/show/NCT00571701.
71. Saldivar J.S., Lopez D., Feldman R.A., et al. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study. Gynecol Oncol 2007, 107(1 Suppl 1):S155-S162.
72. Wu R., Coniglio S.J., Chan A., et al. Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 2007, 13(3-4):143-150.
73. Loddenkemper C., Hoffmann C., Stanke J., et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009, 100(6):1112-1117.
74. Welters M.J., Kenter G.G., de Vos van Steenwijk P.J., et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010, 107(26):11895-11899.
75. Emens L.A., Asquith J.M., Leatherman J.M., et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009, 27(35):5911-5918.
76. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
77. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28(19):3167-3175.